vagal bradycardia
Recently Published Documents


TOTAL DOCUMENTS

63
(FIVE YEARS 0)

H-INDEX

17
(FIVE YEARS 0)

2017 ◽  
Vol 69 (1) ◽  
pp. 13-22 ◽  
Author(s):  
José Ángel García-Pedraza ◽  
Mónica García ◽  
María Luisa Martín ◽  
Nélida Eleno ◽  
Asunción Morán
Keyword(s):  

2009 ◽  
Vol 98 (5) ◽  
pp. 901-903 ◽  
Author(s):  
Cristina Delcò ◽  
Maurice Beghetti ◽  
Riccardo E Pfister
Keyword(s):  

2007 ◽  
Vol 118 (4) ◽  
pp. e12
Author(s):  
K.J. Bär ◽  
M. Böttger ◽  
S. Berger ◽  
H. Sauer ◽  
A. Voss

2006 ◽  
Vol 37 (01) ◽  
Author(s):  
KJ Bär ◽  
M Böttger ◽  
S Berger ◽  
H Sauer ◽  
A Voss

2004 ◽  
Vol 1009 (1-2) ◽  
pp. 137-146 ◽  
Author(s):  
Masayoshi Kobayashi ◽  
Yuichi Majima

2003 ◽  
Vol 285 (5) ◽  
pp. H2001-H2012 ◽  
Author(s):  
Martin Farias ◽  
Keith Jackson ◽  
Michael Johnson ◽  
James L. Caffrey

Endogenous opioids and nitric oxide (NO) are recognized modulators of cardiac function. Enkephalins and inhibitors of NO synthase (NOS) both produce similar interruptions in the vagal control of heart rate. This study was conducted to test the hypothesis that NO systems within the canine sinoatrial (SA) node facilitate local vagal transmission and that the endogenous enkephalin methionine-enkephalin-arginine-phenylalanine (MEAP) attenuates vagal bradycardia by interrupting the NOS-cGMP pathway. Microdialysis probes were inserted into the SA node, and they were perfused with nonselective ( Nω-nitro-l-arginine methyl ester) and neuronal (7-nitroindazole) NOS inhibitors. The right vagus nerve was stimulated and both inhibitors gradually attenuated the resulting vagal bradycardia. The specificity of these inhibitions was verified by an equally gradual reversal of the inhibition with an excess of the NOS substrate l-arginine. Introduction of MEAP into the nodal interstitium produced a quickly developing but quantitatively similar interruption of vagal bradycardia that was also slowly reversed by the addition of l-arginine and not by d-arginine. Additional support for convergence of opioid and NO pathways was provided when the vagolytic effects of MEAP were also reversed by the addition of the NO donor S-nitroso- N-acetyl-penicillamine, the protein kinase G activator 8-bromo-cGMP, or the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine. MEAP and 7-nitroindazole were individually combined with the direct acting muscarinic agonist methacholine to evaluate potential interactions with muscarinic receptors within the SA node. MEAP and 7-nitroindazole were unable to overcome the bradycardia produced by methacholine. These data suggest that NO and enkephalins moderate the vagal control of heart rate via interaction with converging systems that involve the regulation of cAMP within nodal parasympathetic nerve terminals.


2003 ◽  
Vol 285 (3) ◽  
pp. H1332-H1339 ◽  
Author(s):  
M. Farias K. Jackson ◽  
D. Yoshishige ◽  
J. L. Caffrey

Methionine-enkephalin-arginine-phenylalanine (MEAP) introduced into the interstitium of the canine sinoatrial (SA) node by microdialysis interrupts vagal bradycardia. In contrast, raising endogenous MEAP by occluding the SA node artery improves vagal bradycardia. Both are blocked by the same δ-selective antagonist, naltrindole. We tested the hypothesis that vagal responses to intranodal enkephalin are bimodal and that the polarity of the response is both dose- and opioid receptor subtype dependent. Ultralow doses of MEAP were introduced into the canine SA node by microdialysis. Heart rate frequency responses were constructed by stimulating the right vagus nerve at 1, 2, and 3 Hz. Ultralow MEAP infusions produced a 50–100% increase in bradycardia during vagal stimulation. Maximal improvement was observed at a dose rate of 500 fmol/min with an ED50 near 50 fmol/min. Vagal improvement was returned to control when MEAP was combined with the δ-antagonist naltrindole. The dose of naltrindole (500 fmol/min) was previously determined as ineffective vs. the vagolytic effect of higher dose MEAP. When MEAP was later reintroduced in the same animals at nanomoles per minute, a clear vagolytic response was observed. The δ1-selective antagonist 7-benzylidenenaltrexone (BNTX) reversed the vagal improvement with an ED50 near 1 × 10–21 mol/min, whereas the δ2-antagonist naltriben had no effect through 10–9 mol/min. Finally, the improved vagal bradycardia previously associated with nodal artery occlusion and endogenous MEAP was blocked by the selective δ1-antagonist BNTX. These data support the hypothesis that opioid effects within the SA node are bimodal in character, that low doses are vagotonic, acting on δ1-receptors, and that higher doses are vagolytic, acting on δ2-receptors.


Sign in / Sign up

Export Citation Format

Share Document